Massachusetts-based medical device major
Boston Scientific Corporation
) has joined hands with Japanese medical equipment manufacturer
ASAHI INTECC to develop an advanced fractional flow reserve (FFR)
guide-wire. The alliance also aims at improving the key features of
Boston Scientific's RotaWire Atherectomy Guidewire.
Despite this aspiring news, Boston Scientific's share price
dropped 0.3% to eventually close at $12.60 yesterday.
Fractional flow reserve (FFR) is a guide wire-based procedure
that can accurately measure blood pressure and flow of blood
through a specific part of the coronary artery. It is defined as
a fraction of the normal blood flow in an individual's coronary
artery compared to the maximum achievable blood flow in the same
The FFR market is currently witnessing a double-digit growth
rate and is widely viewed as the emerging field in interventional
cardiology that exceeds $250 million globally. FFR guided
percutaneous coronary intervention (PCI) has been found to be
cheaper and more effective as it reduces one-year major adverse
cardiac events (MACE) rates in heart patients.
RotaWire Atherectomy Guidewire
The RotaWire Atherectomy Guidewire is a unique 0.009" wire
which forms a part of the market-leading Rotablator Rotational
Atherectomy System. It is used in treating calcified lesions in
coronary artery disease patients.
Boston Scientific designed the Rotablator Rotational
Atherectomy System for improved percutaneous use in the
peripheral vessels of those heart patients who suffer from
occlusive atherosclerotic disease and are acceptable candidates
for endovascular procedures.
The Joint Venture
The joint venture aims at creating an instrument which will
improve the procedure of FFR, compared to other FFR wires
available in the market. The jointly innovated FFR wire will be
designed for use with Boston Scientific's POLARIS Multi-Modality
Imaging System - which is used for capturing intravascular
The project also intends to combine medical instruments
manufactured by ASAHI INTECC with Boston Scientific's RotaWire
Atherectomy Guidewire to deliver an advanced version of the
latter. This reflects Boston Scientific's continued focus toward
enhancing its products for better treatment procedures of complex
Both organizations have expressed their enthusiasm regarding
this joint project. The mission is to create truly differentiated
medical devices, by leveraging their technologies. With the
collaboration, it is expected that the market will soon witness
more advanced interventional cardiology instruments for improved
Boston Scientific expects to commercially launch both these
specialty wires in 2015.
Currently, Boston Scientific carries a Zacks Rank #3 (Hold).
Better-ranked stocks in the Medical Products industry include ICU
Medical, Inc. (
), AtriCure, Inc. (
), and Abaxis, Inc. (
). While ICU Medical carries a Zacks Rank #1 (Strong Buy), Abaxis
and Atricure hold a Zacks Rank #2 (Buy) each.
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
BOSTON SCIENTIF (BSX): Free Stock Analysis
ABAXIS INC (ABAX): Free Stock Analysis Report
ICU MEDICAL INC (ICUI): Free Stock Analysis
ATRICURE INC (ATRC): Free Stock Analysis Report
To read this article on Zacks.com click here.